Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Novartis Malaria Initiative Der Weg zur Eliminierung von Malaria Silvio Gabriel, BASAID April 2012.

Similar presentations


Presentation on theme: "The Novartis Malaria Initiative Der Weg zur Eliminierung von Malaria Silvio Gabriel, BASAID April 2012."— Presentation transcript:

1 The Novartis Malaria Initiative Der Weg zur Eliminierung von Malaria Silvio Gabriel, BASAID April 2012

2 Malaria is an African tragedy! More than 90% of malaria deaths occur in Africa 2/60a Malaria is preventable and treatable, yet nearly 655,000 lives are lost to the disease every year 2/73a Children under 5 years old and pregnant women are most at risk 1/2a Most of the older treatments (e.g. chloroquine) are not effective anymore because of resistance 3/14a Artemisinin-based Combination Therapies (ACTs) have transformed the treatment of malaria in the past decade Estimated incidence of malaria per 1,000 population in /221-2 Source: WHO Malaria Report >150 Data not available 2 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only

3 The Novartis Malaria Initiative A holistic approach to best serve patients needs Capacity building – patient-focused education and information Best practice sharing workshops for public health officials responsible for malaria control State-of-the-art packaging and patient information developed specifically for not yet literate populations Training material made available free of charge in several local languages Access – affordability and availability are key Treatment provided without profit to governments and NGOs A 25-fold production increase since SMS for life: using mobile technology to help avoid stock-outs at health facility level 14/3a R&D – leading the path to malaria elimination Mass screening and targeted treatment of asymptomatic carriers 10/ 1a; 11/1a Next generation of malaria treatments 12/1179a/22 Treatment – Coartem ®, a story of firsts First fixed-dose ACT brought to market in 1999 and > 95% cure rate* with demonstrated safety profile 4/940a,b; 5/547a,b; 6/251a,254b; 7/246a; 8/1824a First ACT pre-qualified by the WHO for its efficacy, safety and quality 9/1a First dispersible sweet- tasting ACT specifically developed for infants and children 8/1820a * 28-day PCR-corrected in evaluable population 3 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only

4 500 million Coartem ® treatments delivered Impacting more than 1 million lives Treatments in millions 84 Funding uncertain Global policy uncertain 125% 580% 7% 12% 14% Erratic orders Supply challenges ACT policy adoption ACT roll-out in public sector % Increase in production capacity (2001–2011) Deliveries 100 Success in patient impact results in mortality reduction Available production capacity Novartis Malaria Initiative | April %

5 Together with our partners, and with our continued patient-centric approach… 5 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only

6 6

7 The Novartis Malaria Initiative Four pillars of activities 7 | BASAID | Silvio Gabriel | April 2012 | Der Weg zur Eliminierung von Malaria | Business Use Only

8 No one should die of malaria.


Download ppt "The Novartis Malaria Initiative Der Weg zur Eliminierung von Malaria Silvio Gabriel, BASAID April 2012."

Similar presentations


Ads by Google